Clinical Trials

Patients from 40 states & 3 countries

Our patients have traveled from around the world for our leading-edge programs, clinical trials, personalized treatment plans and quality of life and survivorship programs for both adult and pediatric brain tumor patients.

100+ physicians, researchers, scientists and staff

Our team at the Wells Center for Brain Tumor Therapy at UF includes experts in several specialties, including specialty surgical care, radiation therapy, laser ablation therapy, neuro-oncology care, genetic testing and precision medicine.

Over $10 million a year invested in research funding

From immunotherapy to chemotherapy, optune therapy and unique clinical trials, we are leading the country in searching for a cure for brain tumors.

Fast Facts

Our clinical trials portfolio includes:

  • More than 40 research studies
  • More than 10 Pediatric-focused studies
  • Five phase-1 Trials
  • First-In-Human treatments
  • Investigational New Drugs developed at UF

Listed below are the clinical trials that we are currently enrolling at UF, for general questions about clinical trials please contact John Lybarger at John.Lybarger@neurosurgery.ufl.edu 

Featured Trial

IMPACT

Phase I Study —To Assess Safety and Feasibility of IL-8 Receptor Modified Patient-derived Activated CD70 CAR T cell Therapy in CD70+ and MGMT-unmethylated Adult GBM

Subject Inclusion criteria:

  • Age: 18 years and older (Adult, Older Adult)
  • Newly-diagnosed de novo GBM based on the absence of the a previous history of brain tumor (WHO Grade IV glioma) by histopathology or molecular studies. (Secondary GBM not eligible)
  • The tumor must have a supratentorial component.
  • MGMT-unmethylated and CD70 positive (≥20%, 1+)

See full inclusion criteria and learn more about the IMPACT Clinical Trial (Link to the CT.gov https://classic.clinicaltrials.gov/ct2/show/NCT05353530)
Contact Phuong Deleyrolle to hear more about the IMPACT Clinical Trial   (phuong.deleyrolle@neurosurgery.ufl.edu)

PNOC 020

A Phase I/II Study of RNA-lipid particle (RNA-LP) vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM).

Subject inclusion criteria:
  • Age: 21 Years and older (Adult, Older Adult)
  • Histopathologically proven newly-diagnosed de novo GBM (WHO Grade IV glioma) (secondary GBM not eligible) that is MGMT unmethylated.
  • The tumor must have a supratentorial component.
  • Bone Marrow, Renal and Hepatic tests

See full inclusion criteria and learn more about the PNOC 020 Clinical Trial

Contact Marcia Hodik to hear more about the PNOC 020 Clinical Trial.

 


Browse or search current neurosurgery clinical trials

PNOC 020

A Phase I/II Study of RNA-lipid particle (RNA-LP) vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM).

Adult or Pediatric?

Both

Type of Study
  • Treatment
  • Interventional
  • Immunotherapy
Disease

Brain Tumor

Disease Type

Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)